FDA Approves New Subcutaneous Treatment for Crohn's Disease

The U.S. FDA has granted approval for a subcutaneous induction regimen of risankizumab (Skyrizi, AbbVie) for adults suffering from moderately to severely active Crohn's disease. This development introduces an additional treatment option for patients managing this chronic inflammatory bowel condition, potentially improving patient care.